Scribe Therapeutics (NASDAQ:SCTX) Rating Lowered to "Sell" at Wall Street Zen

Scribe Therapeutics logo with background
Image from MarketBeat Media, LLC.

Scribe Therapeutics (NASDAQ:SCTX - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a note issued to investors on Saturday, Wall Street Zen reports.

Other equities research analysts have also issued reports about the company. Weiss Ratings began coverage on Scribe Therapeutics in a research report on Tuesday, October 20th. They set a "sell (e-)" rating on the stock. Wells Fargo & Company assumed coverage on shares of Scribe Therapeutics in a report on Tuesday, August 18th. They set an "overweight" rating and a $60.00 price objective on the stock. Guggenheim initiated coverage on Scribe Therapeutics in a research report on Tuesday, August 18th. They issued a "buy" rating and a $50.00 target price on the stock. Zacks Research upgraded Scribe Therapeutics to a "hold" rating in a research note on Tuesday, September 1st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $60.00 price target on shares of Scribe Therapeutics in a research report on Thursday. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $51.75.

View Our Latest Analysis on SCTX

Scribe Therapeutics Price Performance

NASDAQ:SCTX opened at $12.07 on Friday. Scribe Therapeutics has a 1-year low of $12.00 and a 1-year high of $39.60. The company has a fifty day moving average of $19.56.

Scribe Therapeutics (NASDAQ:SCTX - Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported ($0.68) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.26). The business had revenue of $1.64 million during the quarter. Research analysts expect that Scribe Therapeutics will post -4.60 EPS for the current fiscal year.

Institutional Trading of Scribe Therapeutics

Large investors have recently modified their holdings of the business. Goldman Sachs Group Inc. bought a new position in shares of Scribe Therapeutics during the third quarter valued at about $398,000. State Street Corp bought a new position in shares of Scribe Therapeutics in the 3rd quarter worth approximately $3,150,000. RA Capital Management L.P. bought a new stake in shares of Scribe Therapeutics during the 3rd quarter valued at $33,169,000. Finally, Baker BROS. Advisors LP bought a new position in shares of Scribe Therapeutics during the 3rd quarter valued at about $12,675,000.

About Scribe Therapeutics

(Get Free Report)

Scribe Therapeutics is a biotechnology company focused on developing CRISPR-based gene-editing technologies and potential genetic medicines. Its platform uses engineered CRISPR systems designed to make targeted changes to DNA, with research aimed at applications across multiple disease areas. Founded in 2017 and based in Alameda, California, the company has pursued research and development collaborations with pharmaceutical companies, including Sanofi and Biogen. Scribe Therapeutics is privately held; I could not verify a Nasdaq listing under the symbol SCTX.

See Also

Analyst Recommendations for Scribe Therapeutics (NASDAQ:SCTX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Scribe Therapeutics Right Now?

Before you consider Scribe Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Scribe Therapeutics wasn't on the list.

While Scribe Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines